Accession Number: | 0001104659-23-025371 |
Date: | 2023-02-22 |
Issuer: | SUPERNUS PHARMACEUTICALS, INC. (SUPN) |
Original Submission Date: |
DEC TIMOTHY C
C/O SUPERNUS PHARMACEUTICALS, INC.
9715 KEY WEST AVENUE
ROCKVILLE, MD 20850
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2023-02-22 | A | 500 | a | $0.00 | 1,341 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
RESTRICTED STOCK UNITS | 0.0 | 2023-02-22 | deemed execution date | D | 500 (d) | common stock 500 | $0.00 | 1,500 | direct |
ID | footnote |
---|---|
f1 | includes an aggregate of 841 shares acquired by the reporting person through the issuer's employee stock purchase plan. |
f2 | each restricted stock unit represents the right to receive one share of supernus common stock upon vesting. |
f3 | these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on february 22, 2023. |